Table 3.
Univariate analysis for EFS and OS
| Characteristic | EFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (years): ≥60 vs. 30–59 vs. ≤30 | 1.64 | 1.35–1.98 | <0.001 | 1.82 | 1.49–2.22 | <0.001 |
| WBC (109/L): ≥40 vs. <40 | 2.00 | 1.36–2.92 | 0.001 | 1.91 | 1.32–2.76 | 0.001 |
| Hemoglobin (g/dL): <10 vs. ≥10 | 1.32 | 0.97–1.80 | 0.08 | 1.36 | 0.98–1.89 | 0.06 |
| Platelets (109/L): <100 vs. ≥100 | 1.33 | 1.10–1.60 | 0.003 | 1.28 | 1.06–1.55 | 0.01 |
| Baseline BM blasts: ≥60% vs. <60% | 0.72 | 0.46–1.13 | 0.15 | 0.65 | 0.40–1.06 | 0.08 |
| LDH: ≥2xULN vs. <2xULN | 1.23 | 0.93–1.63 | 0.14 | 1.11 | 0.83–1.48 | 0.48 |
| PS: 2–4 vs. 0–1 | 1.76 | 1.23–2.53 | 0.002 | 1.97 | 1.36–2.84 | <0.001 |
| Diagnosis: B-ALL vs. T-ALL | 1.18 | 0.81–1.71 | 0.40 | 1.24 | 0.85–1.81 | 0.26 |
| Cytogenetics: poor vs. standard | 1.64 | 1.15–2.33 | 0.006 | 1.70 | 1.20–2.42 | 0.003 |
| Treatment: Hyper-CVAD vs. AugBFM | 1.32 | 0.93–1.89 | 0.12 | 1.39 | 0.96–1.98 | 0.08 |
| Cycles to CR/CRp: ≥2 vs. 1 | 1.72 | 1.26–2.35 | 0.001 | 1.69 | 1.23–2.32 | 0.001 |
| MRD at CR/CRp: positive vs. negative | 2.00 | 1.39–2.89 | <0.001 | 2.33 | 1.61–3.37 | <0.001 |
| D14 BM blasts: ≥30%vs. 10–29% vs. <10% | 1.57 | 1.32–1.86 | <0.001 | 1.46 | 1.24–1.74 | <0.001 |
EFS, event-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; WBC, white blood cell; BM, bone marrow; LDH, lactate dehydrogenase; ULN, upper limit of normal; PS, performance status; Hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone; AugBFM, augmented Berlin-Frankfurt-Munster; CR, complete remission; CRp, CR with inadequate platelet recovery; MRD, minimal residual disease; D14, day 14